Replies to post #42006 on Humanigen Inc (HGENQ)

[cowtown jay]

"What will be left in Humanigen ?"

If our float is as once reported, 229M shares, I believe that 110M (~90% of our OS) of those shares could be owned by Humanigen. That might be a whole lot of nothing, at a share price of $0.0001, or so, and no regulatory authorizations or approvals for lenz, and no customer demand.

But that could change instantly with news.

Pick a share price, if the brokerages are forced to buy-in shares, whether from a recall of the loaned shares, or a merger, and remember...the company owns most of the shares. So I'm hoping to sell some shares for about $200, especially if we're still on the Expert Market.

But, THERE'S SO MUCH POTENTIAL, that even if I can't sell at my target price, just our fundamental price could be in the $60 range ($8B, for example.) market cap, if we can get into the covid prevention market with the Novavax vaccine, and/or regulatory approval for CMML, not to mention a PRV, Humanigen could end up with a boat load of cash.

[cowtown jay]

You can never be sure how a bankruptcy court judge is going to rule, even with guys like Barliant (?) helping the company through the process. I appeared once in a corporate bankruptcy case, where the issue concerned naked shorting. The company was being naked shorted tens of millions of shares everyday, even though they were on the Failure-to-Deliver (FTD) list. The judge told me that he thought I (shareholders) had a case. But he couldn't see how naked shorting negatively impacted the issuer. I was dumb-founded, and I mean literally.

So, I can see how transferring intellectual property rights to Taran could have been a safeguard, pending how the judge ruled.

Beyond that, in my opinion, it has made a lot of sense to use Dale's entities as we have, broadly, as what I call our financing arm. I hope, going forward, that we continue to segregate our financing and operational activities, in the manner that we have. But I have to think that the value of Humanigen's shares is a reflection of the value of our intellectual property, and I expect that issue will be addressed as you mentioned, either by way of exclusive licensing, or with a potential merger through subsidiaries of Humanigen and Taran.